Skip to main content
Top
Published in: Discover Oncology 1/2017

01-02-2017 | Original Paper

Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer

Authors: Krassimira Todorova, Metodi V. Metodiev, Gergana Metodieva, Milcho Mincheff, Nelson Fernández, Soren Hayrabedyan

Published in: Discover Oncology | Issue 1/2017

Login to get access

Abstract

Cancer progression is driven by genome instability incurred rearrangements such as transmembrane protease, serine 2 (TMPRSS2)/v-ets erythroblastosis virus E26 oncogene (ERG) that could possibly turn some of the tumor suppressor micro-RNAs into pro-oncogenic ones. Previously, we found dualistic miR-204 effects, acting either as a tumor suppressor or as an oncomiR in ERG fusion-dependent manner. Here, we provided further evidence for an important role of miR-204 for TMPRSS2/ERG and androgen receptor (AR) signaling modulation and fine tuning that prevents TMPRSS2/ERG overexpression in prostate cancer. Based on proximity-based ligation assay, we designed a novel method for detection of TMPRSS2/ERG protein products. We found that miR-204 is TMPRSS2/ERG oncofusion negative regulator, and this was mediated by DNA methylation of TMPRSS2 promoter. Transcriptional factors runt-related transcription factor 2 (RUNX2) and ETS proto-oncogene 1 (ETS1) were positive regulators of TMPRSS2/ERG expression and promoter hypo-methylation. Clustering of patients’ sera for fusion protein, transcript expression, and wild-type ERG transcript isoforms, demonstrated not all patients harboring fusion transcripts had fusion protein products, and only few fusion positive ones exhibited increased wild-type ERG transcripts. miR-204 upregulated AR through direct promoter hypo-methylation, potentiated by the presence of ERG fusion and RUNX2 and ETS1. Proteomics studies provided evidence that miR-204 has dualistic role in AR cancer-related reprogramming, promoting prostate cancer-related androgen-responsive genes and AR target genes, as well as AR co-regulatory molecules. miR-204 methylation regulation was supported by changes in molecules responsible for chromatin remodeling, DNA methylation, and its regulation. In summary, miR-204 is a mild regulator of the AR function during the phase of preserved AR sensitivity as the latter one is required for ERG-fusion translocation.
Appendix
Available only for authorised users
Literature
8.
go back to reference Oberley LW, Oberley TD, Buettner GR (1980) Cell differentiation, aging and cancer: the possible roles of superoxide and superoxide dismutases. Med Hypotheses 6:249–268CrossRefPubMed Oberley LW, Oberley TD, Buettner GR (1980) Cell differentiation, aging and cancer: the possible roles of superoxide and superoxide dismutases. Med Hypotheses 6:249–268CrossRefPubMed
12.
go back to reference Börno ST, Fischer A, Kerick M et al (2012) Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2:1024–1035. doi:10.1158/2159-8290.CD-12-0041 CrossRefPubMed Börno ST, Fischer A, Kerick M et al (2012) Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2:1024–1035. doi:10.​1158/​2159-8290.​CD-12-0041 CrossRefPubMed
19.
go back to reference Smith AM, Findlay VJ, Bandurraga SG et al (2012) ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype. Carcinogenesis 33:572–580. doi:10.1093/carcin/bgs007 CrossRefPubMed Smith AM, Findlay VJ, Bandurraga SG et al (2012) ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype. Carcinogenesis 33:572–580. doi:10.​1093/​carcin/​bgs007 CrossRefPubMed
21.
go back to reference Akech J, Wixted JJ, Bedard K et al (2010) Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29:811–821. doi:10.1038/onc.2009.389 CrossRefPubMed Akech J, Wixted JJ, Bedard K et al (2010) Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29:811–821. doi:10.​1038/​onc.​2009.​389 CrossRefPubMed
22.
go back to reference Todorova K, Zasheva D, Kanev K, Hayrabedyan S (2014) miR-204 shifts the epithelial to mesenchymal transition in concert with the transcription factors RUNX2 , ETS1 , and cMYB in prostate cancer cell line model. J Cancer Res 2014:1–14. doi:10.1155/2014/840906 CrossRef Todorova K, Zasheva D, Kanev K, Hayrabedyan S (2014) miR-204 shifts the epithelial to mesenchymal transition in concert with the transcription factors RUNX2 , ETS1 , and cMYB in prostate cancer cell line model. J Cancer Res 2014:1–14. doi:10.​1155/​2014/​840906 CrossRef
25.
go back to reference Metodieva G, Nogueira-de-Souza NC, Greenwood C et al (2013) CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells. Neoplasia 15:660–668CrossRefPubMedPubMedCentral Metodieva G, Nogueira-de-Souza NC, Greenwood C et al (2013) CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells. Neoplasia 15:660–668CrossRefPubMedPubMedCentral
26.
go back to reference Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.P.B.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367–1372. doi:10.1038/nbt.1511 CrossRefPubMed Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.P.B.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367–1372. doi:10.​1038/​nbt.​1511 CrossRefPubMed
28.
go back to reference Yoav Benjamini YH (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289–300 Yoav Benjamini YH (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289–300
31.
go back to reference Chow A, Amemiya Y, Sugar L et al (2012) Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer. Anticancer Res 32:3629–3642PubMed Chow A, Amemiya Y, Sugar L et al (2012) Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer. Anticancer Res 32:3629–3642PubMed
38.
go back to reference Mounir Z, Korn JM, Westerling T et al (2016) ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor. Elife 5:1–19. doi:10.7554/eLife.13964 CrossRef Mounir Z, Korn JM, Westerling T et al (2016) ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor. Elife 5:1–19. doi:10.​7554/​eLife.​13964 CrossRef
45.
go back to reference Zhang Y, Ng HH, Erdjument-Bromage H et al (1999) Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 13:1924–1935CrossRefPubMedPubMedCentral Zhang Y, Ng HH, Erdjument-Bromage H et al (1999) Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 13:1924–1935CrossRefPubMedPubMedCentral
48.
50.
go back to reference Heebøll S, Borre M, Ottosen PD et al (2008) SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. Histol Histopathol 23:1069–1076PubMed Heebøll S, Borre M, Ottosen PD et al (2008) SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. Histol Histopathol 23:1069–1076PubMed
51.
go back to reference Shaikhibrahim Z, Langer B, Lindstrot A et al (2011) Ets-1 is implicated in the regulation of androgen co-regulator FHL2 and reveals specificity for migration, but not invasion, of PC3 prostate cancer cells. Oncol Rep 25:1125–1129. doi:10.3892/or.2011.1156 PubMed Shaikhibrahim Z, Langer B, Lindstrot A et al (2011) Ets-1 is implicated in the regulation of androgen co-regulator FHL2 and reveals specificity for migration, but not invasion, of PC3 prostate cancer cells. Oncol Rep 25:1125–1129. doi:10.​3892/​or.​2011.​1156 PubMed
Metadata
Title
Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer
Authors
Krassimira Todorova
Metodi V. Metodiev
Gergana Metodieva
Milcho Mincheff
Nelson Fernández
Soren Hayrabedyan
Publication date
01-02-2017
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2017
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-016-0279-9

Other articles of this Issue 1/2017

Discover Oncology 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.